Optum Rx, the pharmacy benefit manager owned by UnitedHealth Group, placed Journavx on some of its commercial formularies in ...
Vertex Pharmaceuticals (NASDAQ:VRTX) ended a four-day winning streak on Thursday after UnitedHealth (NYSE:UNH) placed its new ...
Hosted on MSN1mon
FDA approves Vertex non-opioid pain drugWhat we're watching: It's still an open question whether insurers will cover Journavx. The company has received positive feedback from commercial payers. Vertex is determining whether recent state ...
Vertex's Journavx, a new non-opioid pain drug, lands Tier 3 on Optum Rx formularies. Vertex reports $2.91 billion Q4 sales.
Together these drugs cover the CFTR mutations seen in around half of all CF patients. The next phase of Vertex is focused on the roll-out of its new triple Kaftrio (tezacaftor, ivacaftor and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results